Enceladus is a young, small-scale drug development company. Enceladus introduced Nanocort, a liposomal pharmaceutical that contains anti-inflammatory corticosteroid and selectively targets the actual sites of pathology in severe inflammatory disorders such as rheumatoid arthritis (RA) and multiple sclerosis (MS), and in cancer. Nanocort may offer a novel, highly effective therapeutic intervention strategy. In a range of experimental disease models it was shown that intravenous treatment results in selective accumulation in diseased areas in the body. Consequently, a dramatic increase in intensity and durability of the therapeutic effect was shown, with minimal adverse effects.